376
Kishiki T, Ohnishi H, Masaki T, et al. Overexpression of MET is a new predictive marker for anti-
EGFR therapy in metastatic colorectal cancer with wild-type KRAS. Cancer Chemother
Pharmacol. 2014;73:749–57.
Klinac D, Gray ES, Millward M, Ziman M. Advances in personalized targeted treatment of meta-
static melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54.
Koay EJ, Truty MJ, Cristini V, et al. Transport properties of pancreatic cancer describe gem-
citabine delivery and response. J Clin Invest. 2014;124:1525–36.
Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast
tumours. Nature. 2012;490:61–70.
Korpanty G, Carbon JG, Grayburn PA, et al. Monitoring response to anticancer therapy by target-
ing microbubbles to tumor vasculature. Clin Cancer Res. 2007;13:323–30.
Korsunsky I, McGovern K, LaGatta T, et al. Systems biology of cancer: a challenging expedition
for clinical and quantitative biologists. Front Bioeng Biotechnol. 2014;2:27.
Koski A, Ahtinen H, Liljenback H, et al. [18F]-fl uorodeoxyglucose positron emission tomography
and computed tomography in response evaluation of oncolytic adenovirus treatments of
patients with advanced cancer. Hum Gene Ther. 2013;24:1029–41.
Koya RC, Kimura T, Ribas A, et al. Lentiviral vector-mediated autonomous differentiation of
mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther.
2007;15:971–80.
Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected
non-squamous, non-small-cell lung cancer: development and international validation studies.
Lancet. 2012;379:823–32.
Kretschmar C, Kleinberg L, Greenberg M, et al. Pre-radiation chemotherapy with response-based
radiation therapy in children with central nervous system germ cell tumors: a report from the
Children’s Oncology Group. Pediatr Blood Cancer. 2007;48:285–91.
Kurdziel KA, Ravizzini G, Croft BY, et al. The evolving role of nuclear molecular imaging in
cancer. Expert Opin Med Diagn. 2008;2:829–42.
Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell
lung cancer. N Engl J Med. 2010;363:1693–703.
Labuhn M, Vuaroqueaux V, Fina F, et al. Simultaneous quantitative detection of relevant biomark-
ers in breast cancer by quantitative real-time PCR. Int J Biol Markers. 2006;21:30–9.
Laing RE, Walter MA, Campbell DO, et al. Noninvasive prediction of tumor responses to gem-
citabine using positron emission tomography. Proc Natl Acad Sci U S A. 2009;106:2847–52.
Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes
across 21 tumour types. Nature. 2014;505:495–501.
Leary RJ, Lin JC, Cummins J, et al. Integrated analysis of homozygous deletions, focal amplifi ca-
tions, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A.
2008;105:16224–9.
Lee E, Nichols P, Spicer D, et al. GRP78 as a novel predictor of responsiveness to chemotherapy
in breast cancer. Cancer Res. 2006;66:7849–53.
Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-
like malignancies. Ann Oncol. 2014;25:32–40.
Leong C, Vidnovic N, DeYoung MP, et al. The p63/p73 network mediates chemosensitivity to
cisplatin in a biologically defi ned subset of primary breast cancers. J Clin Invest.
2007;117:1370–80.
Li Y, Zou L, Li Q, et al. Amplifi cation of LAPTM4B and YWHAZ contributes to chemotherapy
resistance and recurrence of breast cancer. Nat Med. 2010;16:214–8.
Liang C, Marsit CJ, McClean MD, et al. Biomarkers of HPV in head and neck squamous cell
carcinoma. Cancer Res. 2012;72:5004–13.
Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic
breast- cancer cells. NEJM. 2007;356:217–26.
Liu XQ, Song WJ, Sun TM, et al. Targeted delivery of antisense inhibitor of miRNA for antiangio-
genesis therapy using cRGD-functionalized nanoparticles. Mol Pharm. 2011;8:250–9.
Long W, Yi P, Amazit L, et al. SRC-3Δ4 mediates the interaction of EGFR with FAK to promote
cell migration. Mol Cell. 2010;37:321–32.
10 Personalized Therapy of Cancer